Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Venlafaxine Extended-Release Effective for Patients with Major Depression

13.12.2007
Major depressive disorder (MDD) is the most common major mental illness, afflicting almost one in five individuals. More than 75% of people who recover from an episode of MDD will have at least one recurrence, with the majority having multiple recurrences.

MDD is the leading cause of disability of all medical illnesses, with substantial functional impairment, morbidity, and mortality. Few studies have assessed the efficacy of antidepressant medications beyond 1 year of maintenance treatment for the prevention of recurrent depression. However, a new study being published in the upcoming December 15th issue of Biological Psychiatry has done just that.

The PREVENT study, an acronym for the title of the study “The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years study,” is, according to one of the senior authors on the paper, Dr. Martin B. Keller, “a multiphase, double-blind, randomized clinical trial designed to investigate the efficacy of the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine extended release in the prevention of depressive recurrence over 2 years in patients with a history of recurrent MDD who have responded to acute and continuation treatment.” The investigators randomly assigned patients with recurrent depression to receive treatment with either venlafaxine extended-release (ER) or fluoxetine, an antidepressant already established as efficacious as a comparative medication. Although the PREVENT study followed patients for over two years, this article reports only on the acute and continuation phases, which were 10 weeks and 6 months long respectively.

Dr. Keller notes that this study “has several novel aspects to its design and methods,” including its very large sample size, and long period of blinded treatment, where neither the physicians nor patients knew which medication the patient was receiving. The authors found that nearly 80% of the patients achieved at least an adequate therapeutic response to acute phase treatment with venlafaxine ER or fluoxetine, and almost none of the responders who continued on treatment for 6 months relapsed.

Husseini K. Manji, M.D., FRCP(C), Deputy Editor of Biological Psychiatry and Director of the Mood and Anxiety Disorders Program at the National Institute of Mental Health, comments on the study’s findings:

"Major depression is a serious, debilitating, life-shortening illness that affects millions of people worldwide. This is thus an important study that shows surprisingly high response and remission rates. For many patients, major depression is a chronic illness characterized by multiple episodes of symptom exacerbation, residual symptoms between episodes, and functional impairment. Thus, the ability to maintain patients in remission is critical to reducing long-term disability."

In addition to the high response rates by the patients in this study, the rates of adverse events (side effects) were similar among the two treatment groups. Dr. Manji does issue a caution though with regard to generalizing the findings, noting that “the investigators studied a group of patients whose course of illness was not chronic. Furthermore, they excluded patients with a history of treatment resistance or significant comorbid illnesses.” However, he added that “if replicated, the results suggest that there may be a subgroup of depressed patients for whom early and sustained treatment can maintain response and prevent relapses." Dr. Keller remarks that these results are “critical to clinical practice and should be considered when choosing a treatment for patients with recurrent MDD.”

Jayne Dawkins | alfa
Further information:
http://www.elsevier.com

More articles from Health and Medicine:

nachricht Skipping Meat on Occasion May Protect Against Type 2 Diabetes
25.06.2019 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke

nachricht Inhaling air pollution-like irritant alters defensive heart-lung reflex for hypertension
19.06.2019 | University of South Florida (USF Innovation)

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fraunhofer IDMT demonstrates its method for acoustic quality inspection at »Sensor+Test 2019« in Nürnberg

From June 25th to 27th 2019, the Fraunhofer Institute for Digital Media Technology IDMT in Ilmenau (Germany) will be presenting a new solution for acoustic quality inspection allowing contact-free, non-destructive testing of manufactured parts and components. The method which has reached Technology Readiness Level 6 already, is currently being successfully tested in practical use together with a number of industrial partners.

Reducing machine downtime, manufacturing defects, and excessive scrap

Im Focus: Successfully Tested in Praxis: Bidirectional Sensor Technology Optimizes Laser Material Deposition

The quality of additively manufactured components depends not only on the manufacturing process, but also on the inline process control. The process control ensures a reliable coating process because it detects deviations from the target geometry immediately. At LASER World of PHOTONICS 2019, the Fraunhofer Institute for Laser Technology ILT will be demonstrating how well bi-directional sensor technology can already be used for Laser Material Deposition (LMD) in combination with commercial optics at booth A2.431.

Fraunhofer ILT has been developing optical sensor technology specifically for production measurement technology for around 10 years. In particular, its »bd-1«...

Im Focus: The hidden structure of the periodic system

The well-known representation of chemical elements is just one example of how objects can be arranged and classified

The periodic table of elements that most chemistry books depict is only one special case. This tabular overview of the chemical elements, which goes back to...

Im Focus: MPSD team discovers light-induced ferroelectricity in strontium titanate

Light can be used not only to measure materials’ properties, but also to change them. Especially interesting are those cases in which the function of a material can be modified, such as its ability to conduct electricity or to store information in its magnetic state. A team led by Andrea Cavalleri from the Max Planck Institute for the Structure and Dynamics of Matter in Hamburg used terahertz frequency light pulses to transform a non-ferroelectric material into a ferroelectric one.

Ferroelectricity is a state in which the constituent lattice “looks” in one specific direction, forming a macroscopic electrical polarisation. The ability to...

Im Focus: Determining the Earth’s gravity field more accurately than ever before

Researchers at TU Graz calculate the most accurate gravity field determination of the Earth using 1.16 billion satellite measurements. This yields valuable knowledge for climate research.

The Earth’s gravity fluctuates from place to place. Geodesists use this phenomenon to observe geodynamic and climatological processes. Using...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on UV LED Technologies & Applications – ICULTA 2020 | Call for Abstracts

24.06.2019 | Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

 
Latest News

Cooling with the sun

25.06.2019 | Power and Electrical Engineering

Robocabs: The mobility of the future?

25.06.2019 | Studies and Analyses

Skipping Meat on Occasion May Protect Against Type 2 Diabetes

25.06.2019 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>